← Back to headlines
Novartis Drug Fabhalta Receives Full FDA Approval for Kidney Disease
Novartis has secured full FDA approval for its kidney disease drug Fabhalta, specifically for the treatment of IgA nephropathy.
17 Jul, 15:59 — 17 Jul, 15:59
Sources
Showing 1 of 1 sources
